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Summary
An opioid is a chemical that binds to opioid receptors,
which are widely distributed in the central and peripheral
nervous system and gastrointestinal tract. The different ef-
fects elicited by activation of these receptors are due to
their specific neuronal and extraneuronal distribution. The
painkiller effect of opioids is induced by the synergy of the
two events, namely reduction of pain threshold and emo-
tional detachment from pain. The opioid effects transcend-
ing analgesia include sedation, respiratory depression,
constipation and a strong sense of euphoria. There are
opioid-like substances endogenously produced by the
body. Naturally occurring peptides, called enkephalins,
have opioid-like activities but are not derived from opium
and exert opioid-like effects by interacting with opioid re-
ceptors on cell membranes. Yet, animals do contain the
same morphine precursors and metabolites as opium pop-
py and are able to synthesize endogenous morphine alka-
loid. Experimental and clinical studies show that opioids,
at doses comparable to those of endogenous opioids, can
activate pronociceptive systems, leading to pain hyper-
sensitivity and short-term tolerance, a phenomenon en-
countered in postoperative pain management by acute
opioid administration. Whether endogenous opioids play a
role in the acute pain necessary to the survival of the indi-
vidual, remains an open question.
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Pert and Snyder were able to identify for the first time the
bond between radioactive opioids and receptors in a mixture
of rodent brain and distinguish specific opioid-receptor inter-
actions from non-specific binding between opioids and brain
membranes (1). These researchers investigated the molecu-
lar structures nearby the recognition site in the same brain
membrane, to identify the second messenger that could con-
vert the information related to the recognition of the receptor
by the opioid into changes in the cell function. This second
messenger was established as the cyclic adenosine
monophosphate (cAMP) whose concentration levels are gov-
erned by an enzymatic machinery that uses the sodium ion.
When opioid agonists bind to the proper receptor, a change
occurs in the key interactions that sodium has with the appa-
ratus of cAMP. Obviously, antagonists bind with equal affini-
ty to the receptor but do not cause changes although they
are able to reverse the effects of opioids (1). The opioids ex-
ert their lethal effect by depressing respiration. Patients in
overdose may return to normal conditions even if they are in
a deep and presumably irreversible coma, when subjected to
an injection of a small amount of intravenous naloxone, an
opiate antagonist able to remove all the molecules by their
respective opiate receptors (1). 
The discovery that opioids were acting through specific re-
ceptors, inducing changes in the cAMP, was not sufficient to
clarify why they abolish pain and give a feeling of well-being
and sometimes euphoria. The step forward was taken when
opiate receptors were localized in the brain (2). A highest
density of opioid receptors was located in areas known to
be involved in integrating information regarding pain. Signal-
ing triggered by pain impulse is transmitted to the spinal
cord through sensory nerves that communicate with the
neurons of the spinal cord. Some nerves are long and pro-
trude towards the brain. Other ones are small and dialogue
with the gelatinous substance of the spinal cord where a
high density of opioid receptors is localized. Another area
with a high concentration of opiate receptors is the medial
thalamus that filters incoming sensory information associat-
ed with intense and deep pain, sending messages to the
cerebral cortex. This last is the type of pain excellently re-
lieved by opioids (3, 4).
Analgesic effect
There are three major classes of opioid receptors that medi-
ate distinct effects: mu (m), delta (d) and k (k) (5). All these
receptors mediate spinal analgesia. Particularly, m opioid re-
ceptor subtype 1 mediates also supraspinal analgesia.
The opioid receptors are coupled to inhibitory G proteins (6).
The receptor activation has many consequences, including
inhibition of adenylate cyclase with reduced generation of
cAMP and other second messengers. Opioids increase the
conduction of potassium and hyperpolarize target cells mak-
ing them less responsive to depolarizing pulses and inhibit-
ing calcium influx. These actions reduce the release of neu-
rotransmitters from neurons and decrease the generation of
the postsynaptic impulse. The analgesic effect of opioids is
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the result of a complex series of neuronal interactions. At
supraspinal level, opioid analgesics bind to m receptor locat-
ed on GABAergic neurons. Usually, these neurons project to
the descendant inhibitory neurons of the brainstem and in-
hibit them. Inhibition of GABAergic neuron induced by bind-
ing of opioid analgesics to opioid receptor, allows the activa-
tion of descendent inhibitory serotoninergic neurons and fi-
nally produces analgesia. At spinal level, analgesic effect is
produced by inhibiting the release of mediators of pain path-
way such as substance P, glutamate and nitric oxide from
nociceptive afferent neurons (7).
Morphine, heroin, fentanyl, codeine and dihydrocodeine are
analgesic opioids acting as full-agonists a m receptor and
have a weak agonist activity at d and k receptors. Buprenor-
phine is a partial agonist at the m receptor and also exert an-
tagonistic activity at m receptor; this last action will enhance
m mediated analgesia. Meptazinol is an analgesic opioid ag-
onist at the m receptor showing also agonist activity on mus-
carinic acetylcholine receptors. Tramadol and methadone
are agonists at m receptors and also inhibit the neuronal re-
uptake of norepinephrine and serotonin enhancing their anal-
gesic activity. Methadone, in addition to its effect via the m
receptor, is also a glutamatergic NMDA receptor antagonist,
action that can further inhibit the transmission of pain (8, 9).
Opioids alleviate pain at the spinal level by raising the
threshold. If an individual is treated with morphine, he will
experience pain in the presence of a painful stimulus more
intense as compared to the one in the absence of morphine
(10). However the main analgesic effect of opiates is not on-
ly an increase in the threshold of pain but also an attenuation
of the subjective evaluation of pain. Patients treated with
morphine because of excruciating pain, relate pain without
trouble associated with it. They have a conscious response
to pain, whereas this response is modified at higher brain
levels (11). The impressive abundance of opiate receptors in
the limbic system suggests an explanation for the emotional
changes caused by opiates. The limbic system, a set of dif-
ferent structures located immediately below the cerebral cor-
tex, contains the highest opioid receptor accumulation than
other parts of the brain (12). The limbic system has nerve
connections with many other parts of the brain such as the
hypothalamus which in turn is closely connected with hy-
pophysis and therefore capable of influencing the hormonal
secretion. Otherwise, other nuclei of the brain such as the lo-
cus coeruleus, which contains an extremely high concentra-
tion of opioid receptors, send networks of nerve endings to
the limbic system (13).
Opioids cause also constriction of the pupil and the pupil pin-
point indicate a powerful, easily visible effect produced by
opioids (14). The pupil diameter is regulated by different
brain districts present in the brainstem some of which, partic-
ularly the pretectal nucleus, are rich in opioid m and k recep-
tor subtype. Numerous groups of nerve cells in the brainstem
are involved in the regulation of respiratory activity and one
of the main area that control respiratory reflexes, the nucleus
of the solitary tract, has a high concentration of m2 subtype
and d opiate receptors (15). Stimulation of m and k receptors
in neuronal plexus of the gut wall induces an increase in the
resting tone of the intestinal wall and sphincter. Increased
segmentation activity and decreased propulsive activity was
observed in intestine and large intestine following opioid ad-
ministration. Therefore, opioid therapy is associated with
constipation and a high percentage of those who take opi-
oids will have to resort to laxatives (16).
Endogenous opioid peptides
The brain produces different endogenous opioid peptides
which are neurotransmitter agents through specific opioid re-
ceptors (17). Hughes and Kosterliz have isolated and suc-
cessfully analyzed brain material with structure similar to opi-
oids and identified it as a mixture of two small peptides each
containing only five aminoacids of which four were exactly
the same in both. The two researchers have called them
enkephalins from the greek words en (in) and kefalè (head).
Each of these pentapeptides contains the aminoacid se-
quence Tyr-Gly- as messenger domain linked to leucine and
methionine and they are called leu-enkephalin and met-
enkephalin. Other agonists, containing the same aminoacid
sequence, are dynorphins A and B and a peptide of 31
aminoacids with a met-enkephalin to its carboxyl termination
which is the most potent agonist beta-endorphin (18). Two
additional peptides endomorphin 1 and 2 have been recently
identified to have a sequence in the domain messenger Tyr-
Pro. The various endogenous opioid peptides show prefer-
ential receptor binding. The beta-endorphins bind equally to
the m and d receptors. Endomorphins bind largely but not ex-
clusively to m receptors (19). Dynorphins bind preferentially
to d receptors. Enkephalins bind primarily to the k receptors.
The different physiological effects elicited by these receptors
are due to their specific neuronal distribution. Enkephaliner-
gic derivatives definitely have painkiller effects though deriv-
atives produced by pharmaceutical companies were dramati-
cally less efficacious than morphine.
Yet, the picture of endogenous opioids should be completed
with endogenous alkaloid morphine. Studies have demon-
strated that animals do contain the same morphine precur-
sors and metabolites as opium poppy. Morphine alkaloids in
animal tissues were first demonstrated by immunological
recognition. The molecular structure of the HPLC purified
compound was confirmed as morphine by liquid and gas
chromatographic retention times and mass spectrometry in
various normal tissues such as rat and rabbit skin, mouse,
bovine and primate brain, hypothalamus and adrenal glands,
invertebrate and human tissues, mammalian lung and hu-
man plasma, human cerebrospinal fluid (20). 
Why there are such a number of different endogenous neu-
rotransmitters as opioid receptor ligands is a question that
has yet no answer. 
Paradoxical effect of morphine
Surprisingly, morphine administration at very low doses in-
duces a paradoxical effect, namely pain threshold is de-
creased inducing hyperalgesia. Experimental and clinical
studies show that opioids can activate pronociceptive sys-
tems, leading to pain hypersensitivity and short-term toler-
ance, a phenomenon encountered in postoperative pain
management by acute opioid administration (21-23). 
Classically, morphine at analgesic dose activates G inhibito-
ry protein coupled to opioid receptors to inhibit adenylyl cy-
clase activity and decrease neuronal cAMP levels. However,
some studies suggest that opioids can exert stimulatory ef-
fects either at doses well below those producing neuronal in-
hibition or after chronic exposure. In cultured dorsal root
ganglion neurons, nanomolar concentrations of opioid ago-
nists increase action potential duration, whereas micromolar
concentrations produce the opposite effect (24). This dual
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action of opioids has been explained on the basis of a bi-
modal opioid receptor model where ultra-low doses of an
opioid agonist activate a Gs-coupled excitatory mode of the
opioid receptor to activate adenylyl cyclase and increase
neuronal excitability. Another study in vivo demonstrates the
presence of a nociceptive inositol signaling pathway stimu-
lated by low concentrations of morphine, through m receptor
(25).
Conclusion
Opioids therefore have a bimodal action. They induce an ex-
citatory action at lower doses which might be compared to
concentrations that endogenous opioids have in human
body. At high doses, the inhibitory effect of exogenous opi-
oids in physiological systems exerts its effects achieving and
also transcending analgesia. Naturally, pain has an impor-
tant and inescapable role and is necessary to the survival of
the individual. Endogenous opioids might have this role and
function. If the perception of pain is a good sign of danger
and warns us of what is wrong, pain accompanying acute
and chronic diseases demands prompt resolution. In these
situations, pain can and should be eased, without fatalism
about its necessity.
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